Sintilimab + Gemcitabine + Cisplatin + Placebo + Carboplatin
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Squamous NSCLC
Conditions
Squamous NSCLC
Trial Timeline
Sep 28, 2018 → Sep 30, 2021
NCT ID
NCT03629925About Sintilimab + Gemcitabine + Cisplatin + Placebo + Carboplatin
Sintilimab + Gemcitabine + Cisplatin + Placebo + Carboplatin is a phase 3 stage product being developed by Innovent Biologics for Squamous NSCLC. The current trial status is completed. This product is registered under clinical trial identifier NCT03629925. Target conditions include Squamous NSCLC.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03629925 | Phase 3 | Completed |
Competing Products
20 competing products in Squamous NSCLC